Clinical Trial: LITT for Ultra-early GBM Recurrence

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07616986) titled 'LITT for Ultra-early GBM Recurrence' on Nov. 24, 2025.

Brief Summary: Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.

LITT offers a minimally invasive alternative that may:

* Treat recurrence without delaying RT/CT

* Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-wee...